Shari Sharp
Surgical · Newport Beach, CANPI 1285664458
Payments from drug & device makers
Across 113 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$747
- Boehringer Ingelheim$579
- Lilly USA, LLC$241
- AstraZeneca$240
- Exact Sciences$193
- Amgen$77
- plus $368 from 12 others
What the payments were for
- Food & beverage$2,446100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $747 |
| Boehringer Ingelheim | 22 | $579 |
| Lilly USA, LLC | 10 | $241 |
| AstraZeneca | 12 | $240 |
| Exact Sciences | 8 | $193 |
| Amgen | 4 | $77 |
| Bayer | 3 | $70 |
| Pfizer | 3 | $65 |
| Seqirus USA Inc | 2 | $34 |
| Merck | 2 | $33 |
| Eisai Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Sanofi | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Novartis | 1 | $13 |
How this compares
$2,446 in reported general payments places this provider in the 80th percentile of 729 surgical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 20 | $40,157 |
| JardianceEmpagliflozin | 22 | $28,884 |
| JanuviaSitagliptin Phosphate | 16 | $25,495 |
| EliquisApixaban | 14 | $18,618 |
| XareltoRivaroxaban | 13 | $12,013 |
| SynthroidLevothyroxine Sodium | 37 | $3,263 |
| Rosuvastatin Calcium | 194 | $2,997 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,931 |
| Levothyroxine Sodium | 200 | $2,457 |
| ValacyclovirValacyclovir Hcl | 27 | $2,188 |
| Atorvastatin Calcium | 210 | $2,004 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,832 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,764 |
| Losartan Potassium | 156 | $1,440 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $1,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $23 | $40,15720 claims |
| Boehringer IngelheimJardiance | $579 | $28,88422 claims |
| MerckJanuvia | $33 | $25,49516 claims |
| PfizerEliquis, Paxlovid | $65 | $20,04731 claims |
| AbbVieSynthroid, Armour Thyroid | $747 | $4,38354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 surgical providers in California.
Other surgical in Newport Beach
- Jocelyn NguyenNewport Beach$8K
- Noelle WandsNewport Beach$7K
- Lauren AmicoVista$989K
- Cheyanne MallasWest Hollywood$199K
- Laura PietrzakMarina del Rey$63K
- Jane HartiganSanta Rosa$27K
- Kenny NgoPalo Alto$25K
- Crispin MarRancho Santa Margarita$23K
- Robert FrostRancho Santa Margarita$22K
- Audie LeeSan Francisco$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.